Bse IPO

Pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Orkla India has enclosed the Certificate received from KFin Technologies, the Registrar and Share Transfer Agent of the Company, for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Corona Remedies has informed that Annual General Meeting (AGM) of the Company was held on Thursday, July 09, 2026 through Video Conferencing / Other Audio Visual Means. The following resolutions as mentioned in the Notice of the 22nd AGM were passed through remote e-voting: To receive, consider and adopt the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon for the financial year ended March 31, 2026; To declare final dividend of ₹10 each (Rupees Ten each) (100%) per Equity Share having face value of ₹10 each for the FY2025-26; To appoint a Director in place of Nirav Mehta (DIN: 01644041), who retires by rotation and being eligible, offers himself for re-appointment;. To appoint Walker Chandiok & Co LLP, Chartered Accountants, as the Statutory Auditors of the Company and to fix their remuneration; To ratify the remuneration payable to the Cost Auditors for the FY2026-27; To appoint Dhara Patel, Company Secretary Firm as Secretarial Auditors of the Company; To approve payment of commission to the Non Executive Directors of the Company; To approve payment of remuneration to Dr. Kirtikumar Mehta (DIN: 00385658), Non Executive Director and Chairman of the Company for the Financial Year 2026-27; Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company for a term of 5 years.

The above information is a part of company’s filings submitted to BSE.

Aastha Spintex has informed that it enclosed the Investor presentation.

The above information is a part of company’s filings submitted to BSE.

Tata Capital has informed that pursuant to Regulations 29(1) and 50(1) of the SEBI Listing Regulations, a meeting of the Board of Directors of the Company will be held on Tuesday, July 28, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company has been closed for the Designated Persons of the Company and their Related Persons (including immediate relatives) from Tuesday, June 23, 2026 until 48 hours after the declaration of the said financial results.

The above information is a part of company’s filings submitted to BSE.